RESUMO
In an aeroponic system, nutrients are directly delivered to the plant roots, which results in the faster growth of crops. Furthermore, aeroponics has been extensively used as a research tool for many difficult-to-propagate plant species. The present investigation shows that the plants grown under the aeroponic system were recorded maximum for all the growth parameters except leaf area which was found maximum under nursery conditions. Among treatments, T3 (three buds per cutting) recorded the maximum for all growth parameters followed by T2 (two buds per cutting) and T1 (one bud per cutting). The interaction effect between propagation systems and the number of buds per cutting showed significant results. S1T3 (three budded cuttings under aeroponic system) recorded maximum for growth parameters viz., intermodal length (4.27 cm), plant height (44.39 cm), number of leaves (16.91), leaf yield (10.79 g/plant), whereas least was recorded by S2T1 i.e., one budded cuttings under nursery (2.39 cm, 35.47 cm, 5.88, 4.84g /plant respectively) at 60 DAT. However, S2T3 recorded a maximum leaf area of 95.96 cm2. From these results, it can be concluded that the aeroponic system could be effectively used for the production of V-1 mulberry saplings.
RESUMO
AIM: The aim of this study was to validate the role of fluorescence in situ hybridization (FISH) in investigating HER2/neu gene amplification (human epidermal growth factor receptor 2) in patients with HER2/neu equivocal breast cancer diagnosed on immunohistochemistry (IHC). MATERIALS AND METHODS: This was a retrospective study conducted from January 2013 to October 2017. A total of 134 patients diagnosed with invasive breast carcinoma and HER2/neu equivocal status on IHC were analyzed. Also, the cases for the years 2016 and 2017 formed a subgroup that was analyzed further to study the impact of pre-analytical factors on IHC and FISH results. RESULTS: A total of 134 women with HER2/neu IHC equivocal breast cancer were included in the study with a median age of 50 years (range 25–81). HER2/neu amplification by FISH was noted in 72 (54%) cases, whereas it was non-amplified in 52 (39%) cases. Ten cases were reported as equivocal even on FISH (ASCO/CAP 2013 guidelines). Polysomy 17 was noted in 55 cases (41%), of which 26 patients were≤50 years and 29 patients were >50 years of age. Twenty (36%) of these 55 cases showed HER2/neu amplification, whereas 26 (48%) cases were non-amplified and 9 (16%) cases were reported as equivocal on FISH. Also, more than half of the polysomy cases were hormone receptor negative. CONCLUSION: IHC is a good screening tool for negative and positive results. Any patient targeted for trastuzumab therapy should undergo confirmation of HER2/neu equivocal status by FISH analysis. We also suggest that if a non-classical FISH pattern is seen, the test should be repeated with a non-centromeric chromosome 17 reference locus probe for better treatment planning.